Pub Date : 2025-03-01Epub Date: 2024-12-20DOI: 10.1177/19458924241305658
Kush Panara, Alan D Workman, David K Lerner, Charles C L Tong, Jadyn Wilensky, Jennifer E Douglas, Nithin D Adappa, James N Palmer, Michael A Kohanski
Background: To reduce recurrence rates of inverted papilloma (IP), some have argued for the use of intraoperative frozen margins; results remain mixed and studies critically lack lengthy surveillance periods.
Objective: We aim to elucidate the impact of prolonged surveillance and intraoperative frozen margins on IP recurrence.
Methods: This is a retrospective analysis of patients who underwent resection of IP at a tertiary care center over a 10-year period from 2008 to 2018 followed by subsequent surveillance. Patient demographics, tumor and operative characteristics, and recurrences were analyzed.
Results: Our analysis includes 199 patients, with 37 recurrences and an average recurrence time of 44.4 months; 57% of patients received intraoperative frozen sections and recurrence rates were similar between those who received frozen sections and those who did not (20.1% vs 15.5%, P = .36). Patients with recurrences within 5 years of surgery were more likely to have received frozen sections than those with recurrences beyond 5 years (P < .01). There was no difference in surgical approach or extent of disease in those who received frozen margins. Patients that received frozen sections were more likely to have multiple sites of attachment (56.5% vs 38.1%, P = .01) and persistent disease following a previous resection at an outside institution (67.0% vs 44.0%, P = .001).
Conclusion: Our average time to recurrence was 44.4 months, significantly longer than surveillance times reported in the literature, indicating that longer periods of surveillance are necessary to capture late recurrences. Our analysis is the first and largest American cohort to look at IP resection in a standardized fashion and find that recurrence rates are similar between patients receiving frozen sections or not.
背景:为了降低内翻性乳头瘤(IP)的复发率,一些人主张术中冷冻缘;结果仍然喜忧参半,研究严重缺乏长期的监测期。目的:探讨长时间观察和术中缘冻结对IP复发的影响。方法:回顾性分析2008年至2018年10年间在三级医疗中心接受IP切除术的患者,并进行后续监测。分析患者人口统计学、肿瘤和手术特征以及复发情况。结果:199例患者,37例复发,平均复发时间44.4个月;57%的患者接受了术中冷冻切片,复发率在接受冷冻切片和未接受冷冻切片的患者之间相似(20.1% vs 15.5%, P = 0.36)。手术5年内复发的患者比复发超过5年的患者更有可能接受冷冻切片(P P = 0.01)和先前在外部机构切除后疾病持续的患者(67.0% vs 44.0%, P = 0.001)。结论:我们的平均复发时间为44.4个月,明显长于文献报道的监测时间,表明需要更长的监测时间来捕捉晚期复发。我们的分析是第一个也是最大的美国队列,以标准化的方式观察IP切除术,发现接受冷冻切片或不接受冷冻切片的患者的复发率相似。
{"title":"Prolonged Surveillance in Inverted Papilloma Reveals Delayed Recurrence and Lack of Benefit to Frozen Section.","authors":"Kush Panara, Alan D Workman, David K Lerner, Charles C L Tong, Jadyn Wilensky, Jennifer E Douglas, Nithin D Adappa, James N Palmer, Michael A Kohanski","doi":"10.1177/19458924241305658","DOIUrl":"10.1177/19458924241305658","url":null,"abstract":"<p><strong>Background: </strong>To reduce recurrence rates of inverted papilloma (IP), some have argued for the use of intraoperative frozen margins; results remain mixed and studies critically lack lengthy surveillance periods.</p><p><strong>Objective: </strong>We aim to elucidate the impact of prolonged surveillance and intraoperative frozen margins on IP recurrence.</p><p><strong>Methods: </strong>This is a retrospective analysis of patients who underwent resection of IP at a tertiary care center over a 10-year period from 2008 to 2018 followed by subsequent surveillance. Patient demographics, tumor and operative characteristics, and recurrences were analyzed.</p><p><strong>Results: </strong>Our analysis includes 199 patients, with 37 recurrences and an average recurrence time of 44.4 months; 57% of patients received intraoperative frozen sections and recurrence rates were similar between those who received frozen sections and those who did not (20.1% vs 15.5%, <i>P</i> = .36). Patients with recurrences within 5 years of surgery were more likely to have received frozen sections than those with recurrences beyond 5 years (<i>P</i> < .01). There was no difference in surgical approach or extent of disease in those who received frozen margins. Patients that received frozen sections were more likely to have multiple sites of attachment (56.5% vs 38.1%, <i>P</i> = .01) and persistent disease following a previous resection at an outside institution (67.0% vs 44.0%, <i>P</i> = .001).</p><p><strong>Conclusion: </strong>Our average time to recurrence was 44.4 months, significantly longer than surveillance times reported in the literature, indicating that longer periods of surveillance are necessary to capture late recurrences. Our analysis is the first and largest American cohort to look at IP resection in a standardized fashion and find that recurrence rates are similar between patients receiving frozen sections or not.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"98-101"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142862993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-12-16DOI: 10.1177/19458924241304082
Rhea Darbari Kaul, Peta-Lee Sacks, Cedric Thiel, Janet Rimmer, Larry Kalish, Raewyn Gay Campbell, Raymond Sacks, Antonio Di Ieva, Richard John Harvey
Background: Radiomics is a quantitative approach to medical imaging, aimed to extract features into large datasets. By using artificial intelligence (AI) methodologies, large radiomic data can be analysed and translated into meaningful clinical applications. In rhinology, there is heavy reliance on computed tomography (CT) imaging of the paranasal sinus for diagnostics and assessment of treatment outcomes. Currently, there is an emergence of literature detailing radiomics use in rhinology.
Objective: This systematic review aims to assess the current techniques used to analyze radiomic data from paranasal sinus CT imaging.
Methods: A systematic search was performed using Ovid MEDLINE and EMBASE databases from January 1, 2019 until March 16, 2024 using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist and Cochrane Library Systematic Reviews for Diagnostic and Prognostic Studies. The QUADAS-2 and PROBAST tools were utilized to assess risk of bias.
Results: Our search generated 1456 articles with 10 articles meeting eligibility criteria. Articles were divided into 2 categories, diagnostic (n = 7) and prognostic studies (n = 3). The number of radiomic features extracted ranged 4 to 1409, with analysis including non-AI-based statistical analyses (n = 3) or machine learning algorithms (n = 7). The diagnostic or prognostic utility of radiomics analyses were rated as excellent (n = 3), very good (n = 2), good (n = 2), or not reported (n = 3) based upon area under the curve receiver operating characteristic (AUC-ROC) or accuracy. The average radiomics quality score was 36.95%.
Conclusion: Radiomics is an evolving field which can augment our understanding of rhinology diseases, however there are currently only minimal quality studies with limited clinical utility.
{"title":"Radiomics of the Paranasal Sinuses: A Systematic Review of Computer-Assisted Techniques to Assess Computed Tomography Radiological Data.","authors":"Rhea Darbari Kaul, Peta-Lee Sacks, Cedric Thiel, Janet Rimmer, Larry Kalish, Raewyn Gay Campbell, Raymond Sacks, Antonio Di Ieva, Richard John Harvey","doi":"10.1177/19458924241304082","DOIUrl":"10.1177/19458924241304082","url":null,"abstract":"<p><strong>Background: </strong>Radiomics is a quantitative approach to medical imaging, aimed to extract features into large datasets. By using artificial intelligence (AI) methodologies, large radiomic data can be analysed and translated into meaningful clinical applications. In rhinology, there is heavy reliance on computed tomography (CT) imaging of the paranasal sinus for diagnostics and assessment of treatment outcomes. Currently, there is an emergence of literature detailing radiomics use in rhinology.</p><p><strong>Objective: </strong>This systematic review aims to assess the current techniques used to analyze radiomic data from paranasal sinus CT imaging.</p><p><strong>Methods: </strong>A systematic search was performed using Ovid MEDLINE and EMBASE databases from January 1, 2019 until March 16, 2024 using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist and Cochrane Library Systematic Reviews for Diagnostic and Prognostic Studies. The QUADAS-2 and PROBAST tools were utilized to assess risk of bias.</p><p><strong>Results: </strong>Our search generated 1456 articles with 10 articles meeting eligibility criteria. Articles were divided into 2 categories, diagnostic (n = 7) and prognostic studies (n = 3). The number of radiomic features extracted ranged 4 to 1409, with analysis including non-AI-based statistical analyses (n = 3) or machine learning algorithms (n = 7). The diagnostic or prognostic utility of radiomics analyses were rated as excellent (n = 3), very good (n = 2), good (n = 2), or not reported (n = 3) based upon area under the curve receiver operating characteristic (AUC-ROC) or accuracy. The average radiomics quality score was 36.95%.</p><p><strong>Conclusion: </strong>Radiomics is an evolving field which can augment our understanding of rhinology diseases, however there are currently only minimal quality studies with limited clinical utility.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"147-158"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-09DOI: 10.1177/19458924241308953
Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa
Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.
Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.
Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.
Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.
Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
{"title":"Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.","authors":"Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa","doi":"10.1177/19458924241308953","DOIUrl":"10.1177/19458924241308953","url":null,"abstract":"<p><strong>Background: </strong>Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.</p><p><strong>Objective: </strong>We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.</p><p><strong>Methods: </strong>A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.</p><p><strong>Results: </strong>52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (<i>n</i> = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (<i>n</i> = 17, 32.7%) or pembrolizumab (<i>n</i> = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.</p><p><strong>Conclusion: </strong>Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"102-108"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-09DOI: 10.1177/19458924241312318
Subin Lim, Daniel Trotier, Matvey Karpov, Joseph Han, Kent Lam
Background: The Sino-nasal Outcome Test (SNOT-22) is a 22-question survey that is utilized to evaluate health-related quality of life of patients with chronic rhinosinusitis (CRS). The Patient Global Impression Symptom Severity (PGISS) is a similar yet versatile instrument that combines features of both a Likert scale and a visual analog to assess symptom severity in CRS patients. While previous studies have evaluated the validity of SNOT-22 as an instrument to measure CRS patients' symptom severity, no studies have evaluated PGISS scale's ability to evaluate and guide treatment plans for CRS patients.
Objective: The primary objective of this study was to analyze the clinical utility of PGISS in assessing subjective symptom severity and objective disease status in CRS patients. We additionally aimed to investigate if PGISS scores could serve as predictors for treatment strategies in CRS patients.
Methods: Electronic medical records of CRS patients were retrospectively reviewed between January 2020 and January 2021 from Eastern Virginia Medical School and Sentara Healthcare. Information on demographics, objective disease metrics, treatment, and labs were collected. Statistical analyses were conducted using SAS 9.4 software.
Results: A total of 150 patients were included in our study. A statistically significant positive correlation was found between PGISS and SNOT-22 scores (r(131) = 0.701, P < .0001). Patients with moderate to severe PGISS scores had significantly higher odds of changing their treatment course (odds ratio [OR] = 6.813, P = .001, and OR = 5.491, P = .018, respectively). Additionally, patients with severe PGISS scores had decreased odds of receiving biological intervention (OR = 0.048, P = .043), but they had considerably higher odds of pursuing surgery (OR = 15.939, P = .046). No significant associations were seen between PGISS scores and receiving topical steroids, systematic steroids, nonsteroidal medical treatment, or imaging interventions (P > .05).
Conclusion: Clinicians may consider using the PGISS scale as an alternative method to the SNOT-22 to evaluate subjective symptom severity and guide treatment plans for patients with CRS.
背景:鼻结果测试(SNOT-22)是一项包含22个问题的调查,用于评估慢性鼻窦炎(CRS)患者的健康相关生活质量。患者整体印象症状严重程度(PGISS)是一种类似但多功能的仪器,结合了李克特量表和视觉模拟的特征来评估CRS患者的症状严重程度。虽然已有研究评估了SNOT-22作为衡量CRS患者症状严重程度的工具的有效性,但没有研究评估PGISS量表评估和指导CRS患者治疗方案的能力。目的:本研究的主要目的是分析PGISS在评估CRS患者主观症状严重程度和客观疾病状态中的临床应用。此外,我们旨在调查PGISS评分是否可以作为CRS患者治疗策略的预测因子。方法:回顾性分析2020年1月至2021年1月来自东弗吉尼亚医学院和Sentara Healthcare的CRS患者的电子病历。收集了人口统计学、客观疾病指标、治疗和实验室的信息。采用SAS 9.4软件进行统计学分析。结果:共纳入150例患者。PGISS与SNOT-22评分呈显著正相关(r(131) = 0.701, P P =。001, OR = 5.491, P =。018年,分别)。此外,PGISS评分严重的患者接受生物干预的几率较低(OR = 0.048, P = 0.043),但他们接受手术的几率较高(OR = 15.939, P = 0.046)。PGISS评分与接受局部类固醇、系统类固醇、非类固醇药物治疗或影像学干预之间无显著相关性(P < 0.05)。结论:临床医生可考虑使用PGISS量表替代SNOT-22量表评估CRS患者主观症状严重程度,指导CRS患者的治疗方案。
{"title":"Evaluation of the Patient Global Impression of Symptom Severity (PGISS) Score as a Subjective and Objective Measure of Disease Activity in Chronic Rhinosinusitis.","authors":"Subin Lim, Daniel Trotier, Matvey Karpov, Joseph Han, Kent Lam","doi":"10.1177/19458924241312318","DOIUrl":"10.1177/19458924241312318","url":null,"abstract":"<p><strong>Background: </strong>The Sino-nasal Outcome Test (SNOT-22) is a 22-question survey that is utilized to evaluate health-related quality of life of patients with chronic rhinosinusitis (CRS). The Patient Global Impression Symptom Severity (PGISS) is a similar yet versatile instrument that combines features of both a Likert scale and a visual analog to assess symptom severity in CRS patients. While previous studies have evaluated the validity of SNOT-22 as an instrument to measure CRS patients' symptom severity, no studies have evaluated PGISS scale's ability to evaluate and guide treatment plans for CRS patients.</p><p><strong>Objective: </strong>The primary objective of this study was to analyze the clinical utility of PGISS in assessing subjective symptom severity and objective disease status in CRS patients. We additionally aimed to investigate if PGISS scores could serve as predictors for treatment strategies in CRS patients.</p><p><strong>Methods: </strong>Electronic medical records of CRS patients were retrospectively reviewed between January 2020 and January 2021 from Eastern Virginia Medical School and Sentara Healthcare. Information on demographics, objective disease metrics, treatment, and labs were collected. Statistical analyses were conducted using SAS 9.4 software.</p><p><strong>Results: </strong>A total of 150 patients were included in our study. A statistically significant positive correlation was found between PGISS and SNOT-22 scores (r(131) = 0.701, <i>P</i> < .0001). Patients with moderate to severe PGISS scores had significantly higher odds of changing their treatment course (odds ratio [OR] = 6.813, <i>P</i> = .001, and OR = 5.491, <i>P</i> = .018, respectively). Additionally, patients with severe PGISS scores had decreased odds of receiving biological intervention (OR = 0.048, <i>P</i> = .043), but they had considerably higher odds of pursuing surgery (OR = 15.939, <i>P</i> = .046). No significant associations were seen between PGISS scores and receiving topical steroids, systematic steroids, nonsteroidal medical treatment, or imaging interventions (<i>P</i> > .05).</p><p><strong>Conclusion: </strong>Clinicians may consider using the PGISS scale as an alternative method to the SNOT-22 to evaluate subjective symptom severity and guide treatment plans for patients with CRS.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"128-135"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-10DOI: 10.1177/19458924241311354
Sophie E Yu, Tolani F Olonisakin, John A Moore, Simon Chiang, Stella E Lee
Background: Thymic stromal lymphopoietin (TSLP) plays an important role in mediating the type-2-inflammatory response. This study examined how TSLP and interleukin (IL)-4 levels in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) correlated with clinical and postoperative outcomes.
Methods: Solid-phase sandwich ELISA was used to analyze TSLP and IL-4 levels in mucus (n = 47), plasma (n = 17), polyp (n = 30), inferior (n = 25), and middle (n = 26) turbinate tissue collected during functional endoscopic sinus surgery (FESS) in CRSwNP patients (n = 76) and controls (n = 11). Inclusion criteria includes patients with medical treatment refractory CRSwNP confirmed by endoscopy or maxillofacial CT. Exclusion criteria include history of immunodeficiency, coagulation disorders, fungal sinusitis, or cystic fibrosis. Levels of TSLP and IL-4 were correlated with SNOT-22, UPSIT, and fractional exhaled nitric oxide (FeNO) using MannWhitney U two-tailed test and linear regression with Spearman correlation coefficient test.
Results: TSLP is elevated in the inferior turbinates (effect size = 2.695, p = 0.0007) of CRSwNP patients compared to controls. IL-4 is expressed at elevated levels in the inferior (effect size = 3.092, p < 0.0001) and middle turbinates (effect size = 2.041, p = 0.019) compared to controls. Mucus TSLP (r = 0.4013, p = 0.0153) and IL-4 (r = 0.6138, p < 0.0001) positively correlate with preoperative FeNO levels. Lower TSLP in the inferior (r = -0.5179, p = 0.0231) and middle turbinates (r = -0.5075, p = 0.0224) and lower IL-4 in the inferior turbinates (r = -0.5205, p = 0.0223) correlate with a greater improvement in SNOT-22 post-FESS.
Conclusion: TSLP and IL-4 are elevated in patients with CRSwNP and correlated with increased preoperative FeNO levels and decreased sinonasal quality of life benefit after FESS. Expression of TSLP and IL-4 may play a role in guiding postoperative expectations in patients with treatment refractory CRSwNP.
{"title":"The Association of TSLP and IL-4 with Patient-Reported Outcome Measures in Chronic Rhinosinusitis with Nasal Polyps.","authors":"Sophie E Yu, Tolani F Olonisakin, John A Moore, Simon Chiang, Stella E Lee","doi":"10.1177/19458924241311354","DOIUrl":"10.1177/19458924241311354","url":null,"abstract":"<p><strong>Background: </strong>Thymic stromal lymphopoietin (TSLP) plays an important role in mediating the type-2-inflammatory response. This study examined how TSLP and interleukin (IL)-4 levels in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) correlated with clinical and postoperative outcomes.</p><p><strong>Methods: </strong>Solid-phase sandwich ELISA was used to analyze TSLP and IL-4 levels in mucus (n = 47), plasma (n = 17), polyp (n = 30), inferior (n = 25), and middle (n = 26) turbinate tissue collected during functional endoscopic sinus surgery (FESS) in CRSwNP patients (n = 76) and controls (n = 11). Inclusion criteria includes patients with medical treatment refractory CRSwNP confirmed by endoscopy or maxillofacial CT. Exclusion criteria include history of immunodeficiency, coagulation disorders, fungal sinusitis, or cystic fibrosis. Levels of TSLP and IL-4 were correlated with SNOT-22, UPSIT, and fractional exhaled nitric oxide (FeNO) using MannWhitney U two-tailed test and linear regression with Spearman correlation coefficient test.</p><p><strong>Results: </strong>TSLP is elevated in the inferior turbinates (effect size = 2.695, p = 0.0007) of CRSwNP patients compared to controls. IL-4 is expressed at elevated levels in the inferior (effect size = 3.092, p < 0.0001) and middle turbinates (effect size = 2.041, p = 0.019) compared to controls. Mucus TSLP (r = 0.4013, p = 0.0153) and IL-4 (r = 0.6138, p < 0.0001) positively correlate with preoperative FeNO levels. Lower TSLP in the inferior (r = -0.5179, p = 0.0231) and middle turbinates (r = -0.5075, p = 0.0224) and lower IL-4 in the inferior turbinates (r = -0.5205, p = 0.0223) correlate with a greater improvement in SNOT-22 post-FESS.</p><p><strong>Conclusion: </strong>TSLP and IL-4 are elevated in patients with CRSwNP and correlated with increased preoperative FeNO levels and decreased sinonasal quality of life benefit after FESS. Expression of TSLP and IL-4 may play a role in guiding postoperative expectations in patients with treatment refractory CRSwNP.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"118-127"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The success rate of chronic rhinitis surgery varies depending on the patients' factor and surgical method. While outcomes for nasal obstruction differ, the association between preoperative severity of other rhinitis symptoms, such as rhinorrhea, sneezing, and nasal itching, measured via the reflective total nasal symptom score (rTNSS) remains unevaluated.
Objective: To evaluate the association between the response rate to surgical treatment of chronic rhinitis and preoperative severity.
Methods: A retrospective cohort study was conducted among adult patients with chronic rhinitis symptoms refractory to medication and nasal spray for over 6 months and received radiofrequency ablation of inferior turbinates with posterior nasal nerve neurolysis. The primary endpoint was the change from baseline in 24-h rTNSS and nasal obstruction symptom evaluation (NOSE) scores. Postoperative surgery response rate, rTNSS score change, and score improvement ratios were also evaluated.
Results: A total of 183 patients (110 males, 60.1%) were included in this study. After 3-month follow-up, the preoperative rTNSS was 6.51 ± 2.74 change to 1.70 ± 1.43, and the NOSE score was 56.48 ± 19.90 change to 4.56 ± 7.74. Both scores and all sub-scores showed significant differences when comparing preoperative, 1-month, and 3-month results (P < 0.05-0.001). The response rate by rTNSS for whole cohort was 78.14 ± 41.44% and 93.99 ± 23.83% at 1- and 3-month follow-up. Subgroup analyses were performed according to individual rTNSS scores and 2 in 1 score groups (ie, 1-2, 3-4, etc) and their relationship to the surgery outcomes. Both preoperative individual score and score groups were significantly associated with all post-operation outcomes (P = 0.022 to <0.001) in linear regression analysis.
Conclusion: Patients with more severe preoperative rhinitis symptoms are associated with better response rate, post-operation symptom score changes, and score improvement ratio.
背景:慢性鼻炎手术的成功率取决于患者的因素和手术方法。虽然鼻塞的结局不同,但术前其他鼻炎症状(如鼻漏、打喷嚏和鼻痒)严重程度之间的关联,通过反射性鼻症状总评分(rTNSS)测量,仍未得到评估。目的:探讨慢性鼻炎手术治疗有效率与术前严重程度的关系。方法:回顾性队列研究慢性鼻炎症状对药物和鼻喷雾剂难治6个月以上,接受射频消融下鼻甲并鼻后神经松解术的成年患者。主要终点是24小时rTNSS和鼻塞症状评估(NOSE)评分较基线的变化。评估术后手术有效率、rTNSS评分变化及评分改善率。结果:共纳入183例患者,其中男性110例,占60.1%。随访3个月后,术前rTNSS由6.51±2.74变为1.70±1.43,NOSE评分由56.48±19.90变为4.56±7.74。术前、术后1个月、术后3个月鼻炎评分及各分项评分差异均有统计学意义(P P = 0.022)。结论:术前鼻炎症状越严重患者的有效率、术后症状评分变化及评分改善率越高。
{"title":"Chronic Rhinitis Surgery: Association Between Preoperative Severity and Response Rate.","authors":"Chien-Yu Huang, Jyun-Yi Liao, Bor-Hwang Kang, Yaoh-Shiang Lin, Jun-Wei Hsieh","doi":"10.1177/19458924241308990","DOIUrl":"10.1177/19458924241308990","url":null,"abstract":"<p><strong>Background: </strong>The success rate of chronic rhinitis surgery varies depending on the patients' factor and surgical method. While outcomes for nasal obstruction differ, the association between preoperative severity of other rhinitis symptoms, such as rhinorrhea, sneezing, and nasal itching, measured via the reflective total nasal symptom score (rTNSS) remains unevaluated.</p><p><strong>Objective: </strong>To evaluate the association between the response rate to surgical treatment of chronic rhinitis and preoperative severity.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted among adult patients with chronic rhinitis symptoms refractory to medication and nasal spray for over 6 months and received radiofrequency ablation of inferior turbinates with posterior nasal nerve neurolysis. The primary endpoint was the change from baseline in 24-h rTNSS and nasal obstruction symptom evaluation (NOSE) scores. Postoperative surgery response rate, rTNSS score change, and score improvement ratios were also evaluated.</p><p><strong>Results: </strong>A total of 183 patients (110 males, 60.1%) were included in this study. After 3-month follow-up, the preoperative rTNSS was 6.51 ± 2.74 change to 1.70 ± 1.43, and the NOSE score was 56.48 ± 19.90 change to 4.56 ± 7.74. Both scores and all sub-scores showed significant differences when comparing preoperative, 1-month, and 3-month results (<i>P</i> < 0.05-0.001). The response rate by rTNSS for whole cohort was 78.14 ± 41.44% and 93.99 ± 23.83% at 1- and 3-month follow-up. Subgroup analyses were performed according to individual rTNSS scores and 2 in 1 score groups (ie, 1-2, 3-4, etc) and their relationship to the surgery outcomes. Both preoperative individual score and score groups were significantly associated with all post-operation outcomes (<i>P</i> = 0.022 to <0.001) in linear regression analysis.</p><p><strong>Conclusion: </strong>Patients with more severe preoperative rhinitis symptoms are associated with better response rate, post-operation symptom score changes, and score improvement ratio.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"109-117"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-12-29DOI: 10.1177/19458924241308952
Ezer H Benaim, Ethan M Kallenberger, Yasine Mirmozaffari, Cristine Klatt-Cromwell, Charles S Ebert, Adam J Kimple, Brent A Senior, Raj S Kasthuri, Brian D Thorp
Background: Epistaxis is one of the most common and debilitating symptoms of hereditary hemorrhagic telangiectasia (HHT), significantly impacting patients' quality of life. While various medical and surgical interventions exist for managing epistaxis in patients with HHT, patients with moderate to severe epistaxis are high health-care utilizers who frequently need surgical treatment.
Objective: To compare the efficacy, complications, and patient-reported outcomes for common surgical interventions utilized in treating epistaxis in patients with HHT.
Methods: Studies were identified in PubMed, Embase, Scopus, Redalyc, and LILACS databases and uploaded to Covidence. A systematic review following PRISMA guidelines was conducted on studies evaluating outcomes in adults with HHT with moderate to severe epistaxis who had undergone surgical interventions. We compared the respective outcomes for pre-operative and post-operative epistaxis severity/intensity, need for further interventions or transfusions, estimated blood loss, length of surgery, complications, and patient satisfaction.
Results: Twenty studies with a total of 546 patients were included. The most common surgeries studied were nasal closure and laser photocoagulation. Seven studies recorded the change in epistaxis severity score and observed a significant reduction postoperatively (3.91, [95% CI 2.73-5.09]). Eleven studies found a decrease in the number of transfusions and a rise in hemoglobin levels post-operatively. Common complications reported were partial dehiscence of a nasal closure, septal perforation, and continued bleeding requiring re-operation. Most patients report improved quality of life and satisfaction with surgical intervention.
Conclusion: Surgery can significantly reduce the severity of epistaxis in patients with HHT and improve quality of life. Further studies should focus on head-to-head comparisons of procedures and standardization of outcome measures.
背景:鼻出血是遗传性出血性毛细血管扩张症(HHT)最常见和最虚弱的症状之一,严重影响患者的生活质量。虽然存在各种医疗和手术干预措施来管理HHT患者的鼻出血,但中度至重度鼻出血患者是高保健利用率的患者,经常需要手术治疗。目的:比较HHT患者鼻出血常用手术治疗的疗效、并发症和患者报告的结果。方法:在PubMed、Embase、Scopus、Redalyc和LILACS数据库中对研究进行鉴定,并上传到Covidence。遵循PRISMA指南,对接受手术干预的中度至重度鼻出血成人HHT患者的研究结果进行了系统评价。我们比较了术前和术后鼻出血严重程度/强度、进一步干预或输血的需要、估计失血量、手术时间、并发症和患者满意度的各自结果。结果:纳入20项研究,共546例患者。研究中最常见的手术是鼻塞和激光光凝。7项研究记录了鼻出血严重程度评分的变化,并观察到术后显著降低(3.91,[95% CI 2.73-5.09])。11项研究发现输血次数减少,术后血红蛋白水平上升。常见的并发症有鼻塞部分裂开、鼻中隔穿孔和持续出血需要再次手术。大多数患者报告手术干预改善了生活质量和满意度。结论:手术治疗可明显减轻HHT患者鼻出血的严重程度,提高患者的生活质量。进一步的研究应侧重于程序的直接比较和结果测量的标准化。
{"title":"Surgical Management of Moderate to Severe Epistaxis in Hereditary Hemorrhagic Telangiectasia: Systematic Review and Meta-Analysis.","authors":"Ezer H Benaim, Ethan M Kallenberger, Yasine Mirmozaffari, Cristine Klatt-Cromwell, Charles S Ebert, Adam J Kimple, Brent A Senior, Raj S Kasthuri, Brian D Thorp","doi":"10.1177/19458924241308952","DOIUrl":"10.1177/19458924241308952","url":null,"abstract":"<p><strong>Background: </strong>Epistaxis is one of the most common and debilitating symptoms of hereditary hemorrhagic telangiectasia (HHT), significantly impacting patients' quality of life. While various medical and surgical interventions exist for managing epistaxis in patients with HHT, patients with moderate to severe epistaxis are high health-care utilizers who frequently need surgical treatment.</p><p><strong>Objective: </strong>To compare the efficacy, complications, and patient-reported outcomes for common surgical interventions utilized in treating epistaxis in patients with HHT.</p><p><strong>Methods: </strong>Studies were identified in PubMed, Embase, Scopus, Redalyc, and LILACS databases and uploaded to Covidence. A systematic review following PRISMA guidelines was conducted on studies evaluating outcomes in adults with HHT with moderate to severe epistaxis who had undergone surgical interventions. We compared the respective outcomes for pre-operative and post-operative epistaxis severity/intensity, need for further interventions or transfusions, estimated blood loss, length of surgery, complications, and patient satisfaction.</p><p><strong>Results: </strong>Twenty studies with a total of 546 patients were included. The most common surgeries studied were nasal closure and laser photocoagulation. Seven studies recorded the change in epistaxis severity score and observed a significant reduction postoperatively (3.91, [95% CI 2.73-5.09]). Eleven studies found a decrease in the number of transfusions and a rise in hemoglobin levels post-operatively. Common complications reported were partial dehiscence of a nasal closure, septal perforation, and continued bleeding requiring re-operation. Most patients report improved quality of life and satisfaction with surgical intervention.</p><p><strong>Conclusion: </strong>Surgery can significantly reduce the severity of epistaxis in patients with HHT and improve quality of life. Further studies should focus on head-to-head comparisons of procedures and standardization of outcome measures.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":"39 2","pages":"159-168"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-11-22DOI: 10.1177/19458924241298817
Jyotsna Mullur, Rie Maurer, Tessa Ryan, Alanna McGill, Jillian C Bensko, Tanya M Laidlaw, Kathleen M Buchheit
Background: Patients with aspirin-exacerbated respiratory disease (AERD) have difficult-to-treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and often require treatment with biologic therapy for asthma or CRSwNP. Healthcare utilization in patients with AERD has not been well described since the advent of respiratory biologics.
Objective: To determine real-world healthcare utilization and quality of life among patients with AERD and to understand the impact of dupilumab, a monoclonal antibody targeting the interleukin 4 receptor, on patient-reported health outcomes and healthcare utilization.
Methods: We conducted a longitudinal survey study of 98 patients with AERD recruited from the Brigham and Women's Hospital AERD registry. Patients completed online questionnaires describing their medication history, healthcare utilization, and quality of life every 3 months for 2 years.
Results: At the end of 24 months, participants who were on dupilumab at the start of the study and those who started dupilumab had a significant reduction in the number of reported poor health days in the preceding month compared to patients not on dupilumab (P < .001 and P < .01, respectively). Participants on dupilumab and those who started dupilumab also had significantly lower overall sinonasal outcome test-22 and asthma control test scores compared to those not on dupilumab over 24 months (P < .05 for both groups).
Conclusion: Dupilumab therapy significantly improves health-related quality of life in patients with AERD, specifically as it pertains to patient assessment of days of overall poor health and quality of life related to sinonasal and asthma symptoms.
{"title":"Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.","authors":"Jyotsna Mullur, Rie Maurer, Tessa Ryan, Alanna McGill, Jillian C Bensko, Tanya M Laidlaw, Kathleen M Buchheit","doi":"10.1177/19458924241298817","DOIUrl":"10.1177/19458924241298817","url":null,"abstract":"<p><strong>Background: </strong>Patients with aspirin-exacerbated respiratory disease (AERD) have difficult-to-treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and often require treatment with biologic therapy for asthma or CRSwNP. Healthcare utilization in patients with AERD has not been well described since the advent of respiratory biologics.</p><p><strong>Objective: </strong>To determine real-world healthcare utilization and quality of life among patients with AERD and to understand the impact of dupilumab, a monoclonal antibody targeting the interleukin 4 receptor, on patient-reported health outcomes and healthcare utilization.</p><p><strong>Methods: </strong>We conducted a longitudinal survey study of 98 patients with AERD recruited from the Brigham and Women's Hospital AERD registry. Patients completed online questionnaires describing their medication history, healthcare utilization, and quality of life every 3 months for 2 years.</p><p><strong>Results: </strong>At the end of 24 months, participants who were on dupilumab at the start of the study and those who started dupilumab had a significant reduction in the number of reported poor health days in the preceding month compared to patients not on dupilumab (<i>P</i> < .001 and <i>P</i> < .01, respectively). Participants on dupilumab and those who started dupilumab also had significantly lower overall sinonasal outcome test-22 and asthma control test scores compared to those not on dupilumab over 24 months (<i>P</i> < .05 for both groups).</p><p><strong>Conclusion: </strong>Dupilumab therapy significantly improves health-related quality of life in patients with AERD, specifically as it pertains to patient assessment of days of overall poor health and quality of life related to sinonasal and asthma symptoms.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"90-97"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-11-08DOI: 10.1177/19458924241276274
Elizabeth A Sell, Li Hui Tan, David M Renner, Jennifer Douglas, Robert J Lee, Michael A Kohanski, John V Bosso, David W Kennedy, James N Palmer, Nithin D Adappa, Susan R Weiss, Noam A Cohen
Background: Viral infections have long been implicated in the development of chronic rhinosinusitis with nasal polyps (CRSwNP). Given widespread exposure to the common cold coronavirus 229E (HCoV229E), we sought to investigate how HCoV-229E is cleared and stimulates interferon pathways in air-liquid interface (ALI) cultures from patients with CRSwNP.
Objective: The objective of this study was to identify whether viral clearance and ISG expression is different in ALI cultures from donors with CRSwNP compared with controls.
Methods: Plaque assays were used to quantify infectious virus released by infected air-liquid interface (ALI) cultures derived from patients with CRSwNP compared to patients without CRS (controls). Additionally, mock and induced levels of Interferon Stimulated Genes (ISGs) mRNA following HCoV-229E infection were quantified by RT-qPCR.
Results: Quantification of infectious virus by plaque assay reveals that CRSwNP ALI cultures were equally susceptible to HCoV-229E infection, and surprisingly viral titers dropped significantly faster than in the control ALI cultures. We further demonstrate that this accelerated viral clearance correlates with increased mRNA expression of at least 4 ISGs following viral infection in the CRSwNP ALIs compared to the control ALIs.
Conclusion: This study paradoxically demonstrates that ALI cultures from patients with CRSwNP are more efficient at clearing the common cold HCoV-229E virus compared to controls. We also demonstrate significantly increased ISG mRNA expression following HCoV-229E infection in CRSwNP. These findings call for further investigation into the effect of unimpaired interferon signaling on the type 2 inflammatory environment in patients with CRSwNP.
{"title":"Common Cold Coronavirus 229E Induces Higher Interferon Stimulating Gene Responses in Human Nasal Epithelial Cells from Patients with Chronic Rhinosinusitis with Polyposis.","authors":"Elizabeth A Sell, Li Hui Tan, David M Renner, Jennifer Douglas, Robert J Lee, Michael A Kohanski, John V Bosso, David W Kennedy, James N Palmer, Nithin D Adappa, Susan R Weiss, Noam A Cohen","doi":"10.1177/19458924241276274","DOIUrl":"10.1177/19458924241276274","url":null,"abstract":"<p><strong>Background: </strong>Viral infections have long been implicated in the development of chronic rhinosinusitis with nasal polyps (CRSwNP). Given widespread exposure to the common cold coronavirus 229E (HCoV229E), we sought to investigate how HCoV-229E is cleared and stimulates interferon pathways in air-liquid interface (ALI) cultures from patients with CRSwNP.</p><p><strong>Objective: </strong>The objective of this study was to identify whether viral clearance and ISG expression is different in ALI cultures from donors with CRSwNP compared with controls.</p><p><strong>Methods: </strong>Plaque assays were used to quantify infectious virus released by infected air-liquid interface (ALI) cultures derived from patients with CRSwNP compared to patients without CRS (controls). Additionally, mock and induced levels of Interferon Stimulated Genes (ISGs) mRNA following HCoV-229E infection were quantified by RT-qPCR.</p><p><strong>Results: </strong>Quantification of infectious virus by plaque assay reveals that CRSwNP ALI cultures were equally susceptible to HCoV-229E infection, and surprisingly viral titers dropped significantly faster than in the control ALI cultures. We further demonstrate that this accelerated viral clearance correlates with increased mRNA expression of at least 4 ISGs following viral infection in the CRSwNP ALIs compared to the control ALIs.</p><p><strong>Conclusion: </strong>This study paradoxically demonstrates that ALI cultures from patients with CRSwNP are more efficient at clearing the common cold HCoV-229E virus compared to controls. We also demonstrate significantly increased ISG mRNA expression following HCoV-229E infection in CRSwNP. These findings call for further investigation into the effect of unimpaired interferon signaling on the type 2 inflammatory environment in patients with CRSwNP.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"13-20"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-10-21DOI: 10.1177/19458924241288664
Jerry Hadi Juratli, Brigit High, Akshita Joshi, Eren Yilmaz, Duzgun Yildirim, Aytug Altundag, Thomas Hummel
Background: Cribriform foramina provide the openings for olfactory nerve fibers to cross from the nasal cavity to the olfactory bulb. Disruption of the olfactory nerve fibers is known to affect olfactory function, but little is known about the potential effects on the number of cribriform foramina in congenital anosmia.
Objective: This pilot study aimed to investigate whether there was a reduction in foramina in patients with acquired and congenital anosmia (including both Kallmann syndrome and isolated congenital anosmia) compared to controls with normal olfactory function.
Methods: Paranasal CT image stacks were analyzed from 20 patients with congenital anosmia (n = 6), acquired anosmia (n = 6), or normal olfactory function (n = 8). Cribriform foramina were counted by three observers from the slice revealing the crista galli and the ethmoidal slits. The two closest values for each subject were analyzed in comparison across the three groups using one-way analysis of variance.
Results: Patients with congenital, but not acquired, anosmia had significantly fewer cribriform foramina (x̄ ± SE = 10.17 ± 1.23) compared to healthy, normosmic controls (x̄ ± SE = 19.88 ± 2.01). There was no significant difference in foramina count between congenital and acquired anosmics (x̄ ± SE = 15.83 ± 3.47).
Conclusion: In this pilot study, a reduced number of cribriform foramina was found in individuals with congenital anosmia. Examination of cribriform foramina could be helpful in counseling patients with olfactory loss. Further investigation in larger studies with additional cohorts is warranted.
背景:楔形孔是嗅神经纤维从鼻腔进入嗅球的开口。已知嗅神经纤维的中断会影响嗅觉功能,但对先天性嗅觉缺失症患者楔形孔数量的潜在影响却知之甚少:这项试验性研究旨在调查与嗅觉功能正常的对照组相比,获得性和先天性嗅觉缺失症(包括卡尔曼综合征和孤立性先天性嗅觉缺失症)患者的楔孔数量是否减少:分析了20名先天性嗅觉缺失(6人)、后天性嗅觉缺失(6人)或嗅觉功能正常(8人)患者的鼻旁CT图像。由三位观察者从显示嵴胆和乙状缝的切片上对嵴孔进行计数。采用单因素方差分析法对每个受试者最接近的两个数值进行比较分析:结果:先天性而非后天性无虹膜症患者的楔形孔(x̄ ± SE = 10.17 ± 1.23)明显少于正常健康对照组(x̄ ± SE = 19.88 ± 2.01)。先天性无肛症患者和后天性无肛症患者的肛门孔数量无明显差异(x̄ ± SE = 15.83 ± 3.47):在这项试验性研究中,发现先天性无肛症患者的楔形孔数量减少。检查楔状孔有助于为嗅觉缺失患者提供咨询。有必要在更大规模的研究中对更多人群进行进一步调查。
{"title":"Cribriform Plate Foramina Count in Patients With Acquired and Congenital Anosmia.","authors":"Jerry Hadi Juratli, Brigit High, Akshita Joshi, Eren Yilmaz, Duzgun Yildirim, Aytug Altundag, Thomas Hummel","doi":"10.1177/19458924241288664","DOIUrl":"10.1177/19458924241288664","url":null,"abstract":"<p><strong>Background: </strong>Cribriform foramina provide the openings for olfactory nerve fibers to cross from the nasal cavity to the olfactory bulb. Disruption of the olfactory nerve fibers is known to affect olfactory function, but little is known about the potential effects on the number of cribriform foramina in congenital anosmia.</p><p><strong>Objective: </strong>This pilot study aimed to investigate whether there was a reduction in foramina in patients with acquired and congenital anosmia (including both Kallmann syndrome and isolated congenital anosmia) compared to controls with normal olfactory function.</p><p><strong>Methods: </strong>Paranasal CT image stacks were analyzed from 20 patients with congenital anosmia (<i>n</i> = 6), acquired anosmia (<i>n</i> = 6), or normal olfactory function (<i>n</i> = 8). Cribriform foramina were counted by three observers from the slice revealing the crista galli and the ethmoidal slits. The two closest values for each subject were analyzed in comparison across the three groups using one-way analysis of variance.</p><p><strong>Results: </strong>Patients with congenital, but not acquired, anosmia had significantly fewer cribriform foramina (x̄ ± SE = 10.17 ± 1.23) compared to healthy, normosmic controls (x̄ ± SE = 19.88 ± 2.01). There was no significant difference in foramina count between congenital and acquired anosmics (x̄ ± SE = 15.83 ± 3.47).</p><p><strong>Conclusion: </strong>In this pilot study, a reduced number of cribriform foramina was found in individuals with congenital anosmia. Examination of cribriform foramina could be helpful in counseling patients with olfactory loss. Further investigation in larger studies with additional cohorts is warranted.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"58-62"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}